ID   RK_BUTOC                Reviewed;          17 AA.
AC   C0HLZ7;
DT   25-MAY-2022, integrated into UniProtKB/Swiss-Prot.
DT   25-MAY-2022, sequence version 1.
DT   03-AUG-2022, entry version 2.
DE   RecName: Full=RK {ECO:0000303|PubMed:30287364};
DE   Flags: Fragment;
OS   Buthus occitanus tunetanus (Common European scorpion) (Buthus tunetanus).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida;
OC   Scorpiones; Buthida; Buthoidea; Buthidae; Buthus.
OX   NCBI_TaxID=6871;
RN   [1]
RP   PROTEIN SEQUENCE, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MASS
RP   SPECTROMETRY, PHARMACEUTICAL, AND DISULFIDE BOND.
RX   PubMed=30287364; DOI=10.1016/j.ijbiomac.2018.09.180;
RA   Khamessi O., Ben Mabrouk H., Othman H., ElFessi-Magouri R., De Waard M.,
RA   Hafedh M., Marrakchi N., Srairi-Abid N., Kharrat R.;
RT   "RK, the first scorpion peptide with dual disintegrin activity on
RT   alpha1/beta1 and alphav/beta3 integrins.";
RL   Int. J. Biol. Macromol. 120:1777-1788(2018).
CC   -!- FUNCTION: Exhibits dual disintegrin activity by reducing the adhesive
CC       function of alpha1beta1 and alphavbeta3 integrins, with higher affinity
CC       for alpha1beta1, thereby inhibiting integrin-dependent cell adhesion
CC       (PubMed:30287364). Inhibits cell adhesion of the human glioblastoma
CC       cell line U87 and the melanoma cell line IGR39 to fibrinogen and
CC       fibronectin, but not to collagen IV or laminin (PubMed:30287364).
CC       Inhibits cell adhesion of the rat pheochromocytoma cell line PC12 to
CC       type IV collagen (PubMed:30287364). Does not exhibit any toxicity in
CC       vivo up to 100 ug/kg body weight within 24 hours in mice
CC       (PubMed:30287364). Does not affect the viability of U87, IGR-39 and
CC       PC12 cell lines at 100 uM after 24, 48 or 72 hours incubation time
CC       (PubMed:30287364). {ECO:0000269|PubMed:30287364}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:30287364}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC       {ECO:0000305|PubMed:30287364}.
CC   -!- MASS SPECTROMETRY: Mass=1780.03; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:30287364};
CC   -!- PHARMACEUTICAL: May have potential for use as an anticancer agent
CC       (PubMed:30287364). Displays anti-tumoral activity by inhibiting cell
CC       adhesion of cancerogenic cell lines without exhibiting toxicity
CC       (PubMed:30287364). {ECO:0000269|PubMed:30287364}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Disulfide bond; Pharmaceutical; Secreted; Toxin.
FT   CHAIN           1..>17
FT                   /note="RK"
FT                   /id="PRO_0000455250"
FT   DISULFID        3..12
FT                   /evidence="ECO:0000269|PubMed:30287364"
FT   NON_TER         17
FT                   /evidence="ECO:0000269|PubMed:30287364"
SQ   SEQUENCE   17 AA;  1782 MW;  97F3315CA4FD72DE CRC64;
     IDCGTVMIPS ECDPKSS